Development of a dry powder for inhalation of nanoparticles codelivering cisplatin and ABCC3 siRNA in lung cancer
Background: The current study sought to formulate a dry powder inhalant (DPI) for pulmonary delivery of lipopolymeric nanoparticles (LPNs) consisting of cisplatin and siRNA for multidrug-resistant lung cancer. siRNA against ABCC3 gene was used to silence drug efflux promoter. Results & discussion: The formulation was optimized through the quality by design system by nanoparticle size and cisplatin entrapment. The lipid concentration, polymer concentration and lipid molar ratio were selected as variables. The DPI was characterized by in vitro deposition study using the Anderson cascade impactor. DPI formulation showed improved pulmonary pharmacokinetic parameters of cisplatin with higher residence time in lungs. Conclusion: Local delivery of siRNA and cisplatin to the lung tissue resulted into an enhanced therapeutic effectiveness in combating drug resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Therapeutic delivery - 12(2021), 9 vom: 31. Sept., Seite 651-670 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Patel, Vivek [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chemosensitization |
|---|
| Anmerkungen: |
Date Completed 27.09.2021 Date Revised 27.09.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/tde-2020-0117 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329186132 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329186132 | ||
| 003 | DE-627 | ||
| 005 | 20231225204553.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/tde-2020-0117 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1097.xml |
| 035 | |a (DE-627)NLM329186132 | ||
| 035 | |a (NLM)34374565 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Patel, Vivek |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of a dry powder for inhalation of nanoparticles codelivering cisplatin and ABCC3 siRNA in lung cancer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.09.2021 | ||
| 500 | |a Date Revised 27.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: The current study sought to formulate a dry powder inhalant (DPI) for pulmonary delivery of lipopolymeric nanoparticles (LPNs) consisting of cisplatin and siRNA for multidrug-resistant lung cancer. siRNA against ABCC3 gene was used to silence drug efflux promoter. Results & discussion: The formulation was optimized through the quality by design system by nanoparticle size and cisplatin entrapment. The lipid concentration, polymer concentration and lipid molar ratio were selected as variables. The DPI was characterized by in vitro deposition study using the Anderson cascade impactor. DPI formulation showed improved pulmonary pharmacokinetic parameters of cisplatin with higher residence time in lungs. Conclusion: Local delivery of siRNA and cisplatin to the lung tissue resulted into an enhanced therapeutic effectiveness in combating drug resistance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Cryo-TEM | |
| 650 | 4 | |a DPI | |
| 650 | 4 | |a MTT assay | |
| 650 | 4 | |a PEG-PLA | |
| 650 | 4 | |a RT-PCR | |
| 650 | 4 | |a chemosensitization | |
| 650 | 4 | |a cisplatin | |
| 650 | 4 | |a gene knockdown | |
| 650 | 4 | |a lung cancer | |
| 650 | 4 | |a siRNA | |
| 650 | 7 | |a Powders |2 NLM | |
| 650 | 7 | |a RNA, Small Interfering |2 NLM | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 700 | 1 | |a Bardoliwala, Denish |e verfasserin |4 aut | |
| 700 | 1 | |a Lalani, Rohan |e verfasserin |4 aut | |
| 700 | 1 | |a Patil, Sushilkumar |e verfasserin |4 aut | |
| 700 | 1 | |a Ghosh, Saikat |e verfasserin |4 aut | |
| 700 | 1 | |a Javia, Ankit |e verfasserin |4 aut | |
| 700 | 1 | |a Misra, Ambikanandan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic delivery |d 2010 |g 12(2021), 9 vom: 31. Sept., Seite 651-670 |w (DE-627)NLM203937082 |x 2041-6008 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g number:9 |g day:31 |g month:09 |g pages:651-670 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/tde-2020-0117 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |e 9 |b 31 |c 09 |h 651-670 | ||